Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 10/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058886 | 0.91 | NR3C2 (0.43) | NR3C2IGF1RCYP17A1CCR2MEN1 | |
| SCHEMBL6058876 | 0.88 | NR3C2 (0.44) | NR3C2IGF1RCYP17A1CCR2PPARG | |
| SCHEMBL12540360 | 0.87 | NR3C2 (0.47) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL12596578 | 0.87 | NR3C2 (0.47) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL6058884 | 0.87 | NR3C2 (0.42) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL27587958 | 0.85 | NR3C2 (0.46) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL30468519 | 0.84 | GABRP (0.47) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL2771914 | 0.84 | GABRP (0.47) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL1940483 | 0.84 | IGF1R (0.48) | NR3C2IGF1RCYP17A1CCR2ATR | |
| SCHEMBL29575346 | 0.84 | IGF1R (0.48) | NR3C2IGF1RCYP17A1CCR2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423012-B2 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | NR3C2 3505/4885IGF1R 2794/4885CYP17A1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.